ABLYNX (D) : ANNOUNCES WEBCAST OF ITS PRESENTATION AT THE 28TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

GHENT,   Belgium,  6 January  2010 ?  Ablynx  [Euronext  Brussels:  ABLX]  today
announced  that it  will webcast  its corporate  presentation at the 28th Annual
J.P.  Morgan Healthcare  Conference on  Wednesday, 13 January 2010 at 11.00 a.m.
PST / 08.00 p.m. CET.

The  presentation, followed by a Q&A, will be  hosted by Dr Edwin Moses, CEO and
Chairman of Ablynx. The presentation will be webcast live and may be accessed on
the  home page of Ablynx?s website at www.ablynx.com <http://www.ablynx.com/>. A
replay  of the webcast will  also be available on  the Company?s website for 30
days, by default (until 12 February 2010).

To  ensure a timely connection,  it is recommended that  users register at least
10 minutes prior to the scheduled webcast.

                                     -ends-

About Ablynx [Euronext Brussels: ABLX] - http://www.ablynx.com<
http://www.ablynx.com/>

Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused
on  the discovery  and development  of Nanobodies,  a novel class of therapeutic
proteins  based on single-domain antibody fragments,  for a range of serious and
life-threatening  human diseases. The Company  currently has over 230 employees.
Ablynx  completed a  successful IPO  on Euronext  Brussels [ABLX]  on 7 November
2007.

Ablynx  is developing a portfolio of  Nanobody-based therapeutics in a number of
major   disease   areas,   including   inflammation,  thrombosis,  oncology  and
Alzheimer?s  disease.  Nanobodies  have  been  generated  against more than 150
different  disease targets. Efficacy data have  been obtained in over 26 in vivo
models for Nanobodies against a range of different targets.

Ablynx  has  an  extensive  patent  position  in  the  field  of  Nanobodies for
healthcare  applications. It has exclusive and worldwide rights to more than 50
families  of  granted  patents  and  pending  patent applications, including the
Hamers  patents covering the basic  structure, composition, preparation and uses
of Nanobodies.

Ablynx  has ongoing  research collaborations  and significant  partnerships with
several  major pharmaceutical  companies, including  Boehringer Ingelheim, Merck
Serono,  Novartis  and  Pfizer  (previously  Wyeth  Pharmaceuticals).  Ablynx is
building  a diverse and broad portfolio  of therapeutic Nanobodies through these
collaborations as well as through its own internal discovery programmes.


For more information, please contact:

College Hill Life Sciences ? for International media enquiries:
Sue Charles, Justine Lamond
t:   [phone]
f:   [phone]
e:  [e-mail] 

Ablynx:
Dr Edwin Moses
Chairman and CEO
t:   [phone]
m: [phone] / [phone]
e:  [e-mail] 

Eva-Lotta Allan
Chief Business Officer
t:   [phone]
m: [phone] / [phone]
e:  [e-mail] 




[HUG#1370935]





    Complete version of the press release: http://hugin.info/137912/R/1370935/335363.pdf